Belay Summit™

multi-analyte tDNA in CSF

Advanced liquid biopsy in CSF

Belay Summit detects mutations and aneuploidy from tumor-derived DNA in CSF to help inform the diagnosis and management of primary and secondary CNS malignancies.

Why choose Belay Summit?

  • Sequencing of tDNA in CSF can identify genetic alterations commonly associated with CNS cancers, and may ultimately preempt tumor biopsy in certain instances1
  • Collection of CSF is well tolerated and currently included in the standard of care for patients with suspicion of CNS tumors
  • Turnaround time is average 7-10 business days from receipt of specimen
  1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073-1113. doi:10.1093/neuonc/noaa106

Stay connected so our team can notify your staff when our test is available.